Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working
GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.
How this was made

The 30-second read
Why it matters
The decision is based on tumor response rates and duration from the ALKOVE-1 single-arm phase 1/2 trial, with pooled safety data and explicit accelerated-approval language that continued approval depends on confirmatory benefit.
Market read
Traders can reassess GSK’s oncology pipeline value and near-term sentiment as Nelkarmi moves from trial to label, while also pricing in accelerated-approval confirmatory risk and safety considerations.
What to watch
Safety signals (notably liver toxicity) and the accelerated-approval dependency on confirmatory clinical benefit could limit adoption and future label durability, affecting near-term commercialization expectations.
Background
The FDA granted accelerated approval to Nelkarmi (neladalkib), a once-daily oral ALK-targeted therapy, for adults with locally advanced or metastatic ALK-positive NSCLC after prior ALK-targeted treatment.
Ticker impact
GSK said the FDA granted accelerated approval to Nelkarmi (neladalkib) for ALK-positive NSCLC after prior ALK-targeted therapy, adding it to its pipeline.
Likely positive bias as investors price in incremental revenue optionality and validate the Nuvalent acquisition’s clinical progress, tempered by confirmatory-trial risk.
The article is a first-report FDA accelerated approval with efficacy and safety details, plus a planned Phase 3 first-line head-to-head (ALKAZAR), which can support sentiment even though accelerated approvals carry follow-on uncertainty.
Market effects
Reinforces competitive intensity in ALK-positive NSCLC targeted therapy sequencing, with attention on durability and tolerability after prior ALK TKIs.
Primarily US regulatory-driven sentiment for global pharma oncology portfolios.
May influence global ALK-positive NSCLC treatment algorithms and payer discussions internationally as the confirmatory evidence path becomes clearer.
Counterpoint
Because this is accelerated approval, the market may overreact to response rates while underweighting the probability and timeline of confirmatory trial success.
Key entities
- drugNelkarmi (neladalkib)
Once-daily oral ALK-targeted therapy receiving FDA accelerated approval for previously treated ALK-positive NSCLC.
- companyGSK
Sponsor that announced the FDA accelerated approval and links Nelkarmi to its Nuvalent acquisition pipeline.
- clinical_trialALKOVE-1
Single-arm phase 1/2 trial used to support the accelerated approval decision.
- clinical_trialALKAZAR
Phase 3 trial comparing Nelkarmi versus Alecensa in previously untreated ALK-positive NSCLC.
- drugAlecensa (alectinib)
Current standard ALK TKI referenced as the comparator and as the only prior ALK TKI subgroup.




